Arotinolol

Summary

Arotinolol (CHEMBL93298) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 371.5 Da · C15H21N3O2S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL93298
Name	Arotinolol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2239
Molecular formula	C15H21N3O2S3
Molecular weight	371.5
InChIKey	BHIAIPWSVYSKJS-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O

IUPAC name: 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide

Also known as: Arotinolol, NSC-317940, AROTINOLOL, arotinolol

Parent form; salt/anhydrous children: CHEMBL3185966

Patent coverage: 1,152 distinct patent families (4,654 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Beta-2 adrenergic receptor, Beta-1 adrenergic receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB1	9.74	Ki	0.18	nM	CHEMBL_ACT_25708414
ADRB2	9.26	Ki	0.55	nM	CHEMBL_ACT_25708415

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).